In February 2017, Johnson & Johnson Innovation led a $25 million Series A funding round for Fusion Pharmaceuticals, a startup focused on targeted cancer radiotherapeutics. The funding supports its ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

Two Massachusetts researchers are among the recipients of an award known as the “Oscars of Science” for their research in ...

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

JBL is set to launch Tune Series 2 in India with ANC, 48-hour battery, and app control starting at ₹5XX9 this month.

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose ...

Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

The technology, which in the past had been limited by size and cost, provides targeted doses of radiation to tumors, ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...